Search research articles
Contact Us
Filters
Showing results (61-70 of 160) with videos related to
Page
of 16
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
May 3, 2016
Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia
Hanna J Khoury, Stuart L Goldberg, Michael J Mauro, et al.
Blood Advances
|
October 25, 2019
The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations
Anca Franzini, Anthony D Pomicter, Dongqing Yan, et al.
Blood
|
June 15, 2006
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations
Heather A Bradeen, Christopher A Eide, Thomas O'Hare, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 8, 2014
Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database
David D Stenehjem, Frederick Albright, Kuan-Ling Kuo, et al.
Blood
|
August 15, 2012
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML
Anupriya Agarwal, Angela G Fleischman, Curtis L Petersen, et al.
Biorxiv : the Preprint Server for Biology
|
August 30, 2023
Bioluminescence Assay of Lysine Deacylase Sirtuin Activity
Alexandria N Van Scoyk, Orlando Antelope, Anca Franzini, et al.
Analytical Biochemistry
|
November 28, 2023
Comparison of colorimetric, fluorometric, and liquid chromatography-mass spectrometry assays for acetyl-coenzyme A
Daniel S Kantner, Emily Megill, Anna Bostwick, et al.
Leukemia
|
December 28, 2023
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile
Ho-Jae Han, Jaeyoon John Kim, Danielle Pyne, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 16, 2015
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors
Monika A Davare, Nadeem A Vellore, Jacob P Wagner, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 18, 2013
Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells
Manabu Kurokawa, Takahiro Ito, Chih-Sheng Yang, et al.
Page
of 16
Search research articles
Search
Showing results (61-70 of 160) with videos related to
Sort By:
Page
of 16
Clinical Lymphoma, Myeloma & Leukemia
|
May 3, 2016
Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia
Hanna J Khoury, Stuart L Goldberg, Michael J Mauro, et al.
Blood Advances
|
October 25, 2019
The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations
Anca Franzini, Anthony D Pomicter, Dongqing Yan, et al.
Blood
|
June 15, 2006
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations
Heather A Bradeen, Christopher A Eide, Thomas O'Hare, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 8, 2014
Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database
David D Stenehjem, Frederick Albright, Kuan-Ling Kuo, et al.
Blood
|
August 15, 2012
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML
Anupriya Agarwal, Angela G Fleischman, Curtis L Petersen, et al.
Biorxiv : the Preprint Server for Biology
|
August 30, 2023
Bioluminescence Assay of Lysine Deacylase Sirtuin Activity
Alexandria N Van Scoyk, Orlando Antelope, Anca Franzini, et al.
Analytical Biochemistry
|
November 28, 2023
Comparison of colorimetric, fluorometric, and liquid chromatography-mass spectrometry assays for acetyl-coenzyme A
Daniel S Kantner, Emily Megill, Anna Bostwick, et al.
Leukemia
|
December 28, 2023
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile
Ho-Jae Han, Jaeyoon John Kim, Danielle Pyne, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 16, 2015
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors
Monika A Davare, Nadeem A Vellore, Jacob P Wagner, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 18, 2013
Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells
Manabu Kurokawa, Takahiro Ito, Chih-Sheng Yang, et al.
Page
of 16